Compare TRS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRS | OGN |
|---|---|---|
| Founded | 1986 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2004 | 2020 |
| Metric | TRS | OGN |
|---|---|---|
| Price | $35.68 | $6.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $41.50 | $11.75 |
| AVG Volume (30 Days) | 467.3K | ★ 3.1M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | 0.45% | ★ 1.26% |
| EPS Growth | ★ 400.00 | N/A |
| EPS | ★ 2.95 | 0.72 |
| Revenue | $645,720,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $5.42 | $0.42 |
| Revenue Next Year | $4.27 | $1.67 |
| P/E Ratio | $12.10 | ★ $8.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.45 | $5.69 |
| 52 Week High | $42.00 | $13.28 |
| Indicator | TRS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 46.64 |
| Support Level | $35.17 | $6.18 |
| Resistance Level | $37.20 | $7.87 |
| Average True Range (ATR) | 1.01 | 0.26 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 58.33 | 79.76 |
TriMas Corp designs, develops and manufactures a diverse set of products for the consumer products, and industrial markets . The company operates through two segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners. The packaging segment generates majority of its revenue.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.